- Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
For: Non-small Cell Lung CancerUnited States · Argentina · Austria - RecruitingPHASE1, PHASE2
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
This study looks at new ways to treat head and neck cancer using a drug called Amivantamab, sometimes combined with other treatments. It aims to find out if these treatments are safe and how well they work for people with different types of head and neck cancer.
For: Squamous Cell Carcinoma of Head and NeckUnited States · China · France - Active not recruitingPHASE2
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
This study is testing a new drug, BNT327, for advanced breast cancer (called triple-negative). Researchers want to see if it's safe and works well when given with chemotherapy. It's for people whose cancer has spread or is difficult to treat.
For: Locally Advanced Breast Cancer · Triple Negative Breast Cancer · Metastatic Triple Negative Breast CancersUnited States · Australia · Turkey (Türkiye) - Active not recruitingPHASE1, PHASE2
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This study is looking into a new drug, AZD5305, by itself or with other cancer treatments, for advanced solid cancers like ovarian, breast, and lung cancer. It aims to see if it's safe, tolerable, and effective.
For: Ovarian Cancer · Breast Cancer · Pancreatic CancerUnited States · Australia · Canada - Active not recruitingPHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is testing a new drug, AZD0901, for advanced stomach cancer or where the food pipe meets the stomach. It's for people whose cancer has Claudin18.2 protein and has already been treated before. Researchers want to see if AZD0901 works better and is safer than other treatments.
For: Gastric Cancer · Gastroesophageal Junction CancerUnited States · Brazil · Canada - RecruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
This study looks at new treatments for a type of womb cancer that has spread or returned. It compares a new drug combination (sac-TMT with pembrolizumab) against pembrolizumab alone to see if it helps patients live longer and keeps the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
For: Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal NeoplasmsUnited States · Australia · Austria - Active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
For: Malignant Solid Tumor · Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC)United States · Denmark · France - Active not recruitingPHASE3
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
This study is looking into a new combination treatment for a type of breast cancer called triple-negative breast cancer (TNBC) that has spread or is advanced. It combines a new drug, Capivasertib, with a common chemotherapy, Paclitaxel, to see if it works better than just Paclitaxel alone.
For: Triple Negative Breast NeoplasmsUnited States · Argentina · Brazil - RecruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
For: Non-small Cell Lung Cancer · NSCLCUnited States · Argentina · Austria - RecruitingPHASE1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
This study looks at a new drug, BNT116, for advanced lung cancer. It explores if BNT116 is safe, how much to give, and how well it works when used alone or with other treatments for different types of non-small cell lung cancer.
For: Non-Small Cell Lung CancerUnited States · Australia · Germany - Active not recruitingPHASE2
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
This study is looking into a new treatment for an aggressive type of breast cancer called triple-negative breast cancer. It combines standard chemotherapy with two newer drugs, Atezolizumab and Ipatasertib, to see if this mix can fight the cancer better before surgery.
For: Triple Negative Breast CancerUnited Kingdom - Active not recruitingPHASE3
Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer
This study looks into adding a short course of chemotherapy (Paclitaxel and Carboplatin) before standard chemoradiation for women with locally advanced cervical cancer. The aim is to see if this extra step improves how long women live and if the cancer stays away.
For: Cervical CancerBrazil · India · Italy - RecruitingPHASE3
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
This study looks at the best way to treat penile cancer that has spread to nearby lymph nodes. It compares surgery alone with surgery after chemotherapy or chemoradiotherapy. It also checks if extra surgery in the pelvis helps prevent cancer from coming back.
For: Squamous Cell Carcinoma of the Penis, Usual TypeUnited States · United Kingdom - Active not recruitingPHASE2, PHASE3
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
This study, called ASPEN-06, looked into an experimental drug called Evorpacept for people in the UK with advanced stomach cancer (gastric cancer) that has a specific genetic marker (HER2-positive). It aimed to see if adding Evorpacept to standard treatments improved outcomes. The study has now been stopped due to strategic reasons.
For: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Gastric AdenocarcinomaUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This study is looking at a new medicine called R-DXd for certain types of advanced ovarian, primary peritoneal, or fallopian tube cancer that haven't responded well to platinum chemotherapy. It aims to find out if R-DXd is safe and effective.
For: Solid CancerUnited States · Australia · Brazil - RecruitingPHASE2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
This study is looking into a new medicine called Volrustomig for various advanced cancers, including cervical, head and neck, oesophageal, and mesothelioma. It aims to see how well it works and if it's safe, both on its own and with standard chemotherapy.
For: Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) · Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) · Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)United States · Australia · Brazil - RecruitingPHASE3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
This study looks at a new treatment called intismeran autogene, given with pembrolizumab, after surgery for non-small cell lung cancer. We want to see if this combination stops the cancer from coming back compared to pembrolizumab alone.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study looks at new drug combinations for metastatic triple-negative breast cancer. It combines standard treatment with new medicines (like Durvalumab) to see if they're safe and work well together for patients whose cancer has spread.
For: Triple Negative Breast NeoplasmsUnited States · Canada · Poland - Active not recruitingPHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
This study is looking at a new treatment for early-stage lung cancer that can be removed with surgery. It combines standard chemotherapy with a newer drug called nivolumab. Researchers want to see if this combination helps people live longer without their cancer returning.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
This study is looking into a new medicine, LOXO-783, for breast cancer and other solid tumours with a specific gene change (PIK3CA). It aims to understand if the medicine is safe, what side effects it has, and how well it works.
For: Breast CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study looks at a new drug, trastuzumab deruxtecan, for people in the UK with HER2-positive stomach or food pipe cancer. It compares this drug to standard treatments for patients whose cancer has grown despite previous therapy. The aim is to see if the new drug works better and is safe.
For: Gastric Cancer, Adenocarcinoma · Gastroesophageal Junction AdenocarcinomaArgentina · Belgium · Brazil - RecruitingPHASE3
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
This study looks at a new drug combination, avutometinib and defactinib, for low-grade serous ovarian cancer that has come back. It compares this new treatment to standard options to see which works best and is safest for patients.
For: Low Grade Serous Ovarian CancerUnited States · Australia · Belgium - Active not recruitingPHASE2
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This study is for people with cancer that has spread, who are already benefiting from a specific medicine called trastuzumab emtansine (T-DM1) or other similar treatments in an earlier study. It allows them to keep receiving these important treatments for longer to see if they continue to help.
For: Neoplasm MetastasisUnited States · Australia · Belgium - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer (squamous non-small cell lung cancer) that has spread. It compares two different drug combinations, including a new medicine called rilvegostomig, to see if they can help patients live longer and improve their quality of life.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
This study is testing two different combinations of medicines, volrustomig plus chemotherapy, or pembrolizumab plus chemotherapy, for people with an advanced type of lung cancer. The aim is to see which combination is safer and works better as a first treatment.
For: Metastatic Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
This study looks at new ways to treat advanced lung cancer that can't be removed by surgery. It combines standard chemotherapy and radiation with newer drugs, pembrolizumab and olaparib, to see if they can improve survival compared to current treatments.
For: Lung Neoplasms · Carcinoma, Non-Small-Cell LungUnited States · Argentina · Canada - RecruitingPHASE1, PHASE2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
This study looks at new ways to treat ovarian cancer that has come back after earlier treatments. It tests a new drug called Raludotatug deruxtecan (R-DXd) by itself or with other standard treatments, to see if it's safe and helps shrink the cancer.
For: Ovarian Cancer RecurrentUnited States · Israel · Spain - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
This study tested new drug combinations for advanced oesophageal cancer. It looked at pembrolizumab with lenvatinib and chemotherapy, versus pembrolizumab and chemotherapy, to see which worked best and was safest. The study has now stopped, with no safety concerns being the reason.
For: Metastatic Esophageal Squamous Cell CarcinomaUnited States · Argentina · Canada - Active not recruitingPHASE3
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
This study compares two chemotherapy treatments for germ cell tumours that have returned or didn't respond to previous treatment. It looks at a standard chemotherapy plan versus a stronger plan with a stem cell transplant to see which works better.
For: Germ Cell Tumor · Teratoma · ChoriocarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
This study looks at a new drug, trastuzumab deruxtecan, for advanced breast cancer that is HER2-low and hormone receptor positive. We want to see if it works better and is safer than standard chemotherapy for people whose cancer has progressed after other treatments.
For: Advanced or Metastatic Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
This study compares a new drug, Puxitatug Samrotecan, with standard chemotherapy for advanced endometrial cancer that has returned after previous treatments. It aims to see if the new drug can help patients live longer or stop their cancer from getting worse.
For: Endometrial Cancer · Malignant Solid TumourUnited States · Argentina · Australia - RecruitingPHASE3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
This study is looking into a new drug, AZD5335, for women with advanced ovarian cancer that has become resistant to usual chemotherapy. It compares AZD5335 to existing treatments to see if it works better at controlling the cancer's growth.
For: Epithelial Ovarian CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
This study looks at a new drug, sacituzumab govitecan, for women with endometrial cancer that has come back or hasn't responded to earlier treatments. It compares this new drug to standard treatments chosen by doctors, aiming to see if it helps women live longer or keeps cancer from growing.
For: Endometrial CancerUnited States · Australia · Brazil - RecruitingPHASE1
Study of INCB123667 in Subjects With Advanced Solid Tumors
This study is testing a new drug, INCB123667, for people with advanced solid tumours. It will look at how safe the drug is, how it's used with other treatments, and if it could help shrink tumours. It's an early-stage study.
For: Solid TumorsUnited States · France · Italy - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
This study is for people with advanced HR+/HER2- breast cancer. It compares a new drug, sacituzumab tirumotecan (alone or with pembrolizumab), against standard chemotherapy, to see which treatment best controls the cancer's growth.
For: Breast NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
This study looks at a new treatment for a type of breast cancer that has come back or spread. It combines a drug called pembrolizumab with standard chemotherapy to see if it works better than chemotherapy alone for HR+/HER2- breast cancer.
For: Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
This study looks at new drug combinations for advanced or returning endometrial cancer that has a specific HER2 marker. It aims to see if these new treatments work better than standard chemotherapy by slowing down cancer growth.
For: Endometrial CancerUnited States · Australia · Austria - RecruitingPHASE2
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
This study is for people with HER2-positive breast cancer that has spread. It's testing a new drug called evorpacept alongside standard treatments like trastuzumab and chemotherapy. Researchers want to see if this combination is safe and helps people whose cancer has grown despite previous treatments.
For: Breast Cancer, MetastaticUnited States · Canada · France - Active not recruitingPHASE2
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
This study is testing new combinations of treatments for head and neck cancer that has come back or spread. It compares two new drugs plus chemotherapy against one new drug plus chemotherapy. The aim is to find safer and more effective ways to treat this type of cancer.
For: Head and Neck Squamous Cell CarcinomaUnited States · Australia · China - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
This study is looking at a new treatment called pembrolizumab for advanced or recurrent womb cancer that has a specific genetic marker. It compares this new treatment to standard chemotherapy to see which works better and is safer for women who haven't had chemotherapy for this stage of cancer before.
For: Endometrial NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
For: Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
This study is for women with cervical cancer that has spread. It's testing new combinations of medicines (sac-TMT, pembrolizumab, and possibly bevacizumab) to see if they are safe and can help people live longer or stop their cancer from getting worse.
For: Cervical CancerUnited States · Argentina · Austria - RecruitingPHASE2, PHASE3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
This study is testing a new drug called pumitamig, combined with usual chemotherapy and other drugs, for people with a type of lung cancer called non-small cell lung cancer. It aims to see if this new combination is safe and works well.
For: Non-small Cell Lung CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
This study looks at a new drug, patritumab deruxtecan, for a certain type of advanced breast cancer. It aims to see if this new treatment helps people live longer or stops cancer from growing compared to standard treatments like chemotherapy.
For: Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
For: Non Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
This study looks at new treatments, sacituzumab tirumotecan alone or with pembrolizumab, for triple-negative breast cancer. It compares their effectiveness with standard chemotherapy to see if they help people live longer or stop cancer growth.
For: Triple Negative Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
This study is looking at a new treatment (BNT323) for women with advanced womb cancer that has come back. It compares BNT323 to standard chemotherapy to see if it works better at shrinking tumours and keeping the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
For: Metastatic Non-small Cell Lung Cancer With MTAP DeletionUnited States · Argentina · Australia - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
For: Breast CancerUnited States · Argentina · Australia